Here’s what you need to know.
1. The company’s GI products include: Linzess, Viberzi, Asacol/Delzicol, Carafate/Sulcrate, Canasa/Salofalk and Zenpep.
2. In the third quarter, Allergan reported revenues of $431.4 million in 2016 compared to $398.6 million in 2015.
3. All Allergan GI products except Asacol/Delzicol reported positive growth.
More articles on gastroenterology/endoscopy:
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
GI leader to know: Dr. Carl Gessner of LeBauer HealthCare
